Browsing by Subject "Aspirin"

Sort by: Order: Results:

Now showing items 1-8 of 8
  • Tiili, Paula; Lehto, Mika; Meretoja, Atte; Nieminen, Tuomo; Pakarinen, Sami; Tatlisumak, Turgut; Putaala, Jukka (2016)
  • EuGMS Special Interest Grp; Alves, Mariana; Fernandes, Marilia Andreia; Bahat, Gülistan; Strandberg, Timo E. (2021)
    Purpose In the pathogenesis of severe COVID-19 complications, derangements of renin-angiotensin-aldosterone system (RAAS), vascular endothelial dysfunction leading to inflammation and coagulopathy, and arrhythmias play an important role. Therefore, it is worth considering the use of currently available drugs to protect COVID-19 patients with cardiovascular diseases. Methods We review the current experience of conventional cardiovascular drugs [angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, anticoagulants, acetosalicylic acid, antiarrhythmic drugs, statins] as well as some other drug classes (antidiabetic drugs, vitamin D and NSAIDs) frequently used by older patients with cardiovascular diseases. Data were sought from clinical databases for COVID-19 and appropriate key words. Conclusions and recommendations are based on a consensus among all authors. Results Several cardiovascular drugs have a potential to protect patients with COVID-19, although evidence is largely based on retrospective, observational studies. Despite propensity score adjustments used in many analyses observational studies are not equivalent to randomised controlled trials (RCTs). Ongoing RCTs include treatment with antithrombotics, pulmonary vasodilators, RAAS-related drugs, and colchicine. RCTs in the acute phase of COVID-19 may not, however, recognise the benefits of long term anti-atherogenic therapies, such as statins. Conclusions Most current cardiovascular drugs can be safely continued during COVID-19. Some drug classes may even be protective. Age-specific data are scarce, though, and conditions which are common in older patients (frailty, comorbidities, polypharmacy) must be individually considered for each drug group. Key summary pointsAim To review current cardiovascular medications for benefits and potential harms during COVID-19. Findings Several cardiovascular drugs have a potential to protect patients with COVID-19, although evidence is largely based on observational studies and age-specific data are scarce. Message Most current cardiovascular drugs can be safely continued during COVID-19, but general conditions common in older patients must be considered.
  • Murtoniemi, K.; Vahlberg, T.; Hämäläinen, E.; Kajantie, E.; Pesonen, A.K.; Räikkönen, K.; Taipale, P.; Villa, P.M.; Laivuori, H. (2018)
    Objectives: Our first aim was to study the longitudinal changes of serum placental growth factor (PlGF) concentration between 12(+0) and 28(+0) weeks of gestation in the prospective PREDO cohort. Our second aim was to study the effect of low-dose acetylsalicylic acid (LDA; 100 mg/day), started before the 14th week of gestation, on PlGF concentration. Study design: Blood samples were collected at 12(+0)-14(+0), 18(+0)-20(+0) and 26(+0)-28(+0) weeks of gestation in 101 women without and 309 with clinical risk factors for pre-eclampsia. Risk-women were divided into two groups: to those who had medium risk for pre-eclampsia and to those who had high risk for pre-eclampsia. Finally there were seven groups according to risk, treatment (no prevention/placebo/LDA) and outcome measure pre-eclampsia. Longitudinal changes in the PlGF concentration between groups were compared. To investigate the effect of LDA on serum PlGF concentration, placebo (N = 62) and LDA (N = 61) groups were compared. A repeated measures ANOVA was used to analyze differences in PlGF levels between the groups. Results: The increase in serum PlGF concentration was higher in LDA than in placebo group (time x group effect, p = 0.046). The increase in serum PlGF concentration during pregnancy was lower in high-risk women who had placebo and developed pre-eclampsia and in medium-risk women who developed pre-eclampsia compared to the other women (time x group effect, p <0.001). There were no differences in PlGF change between low-risk women, medium-risk women who did not develop pre-eclampsia, high-risk women in the placebo group without pre-eclampsia and high-risk women in the LDA group with and without pre-eclampsia (p = 0.15). Conclusions: Our finding suggests an association between LDA started before 14 weeks of gestation and higher increase in serum PlGF concentration.
  • Lund, Juha; Pakarinen, Sami; Inkovaara, Jaakko (2018)
  • Lempiäinen, Juha (2022)
    30-vuotias nainen alkoi kärsiä toisen silmän näönmenetyskohtauksista. Kohtausten aikana vasemman silmän näkö meni asteittain harmaaksi ja palautui sen jälkeen asteittain normaaliksi seuraavien minuuttien kuluessa. Silmälääkäri totesi silmien olevan kunnossa ja lähetti potilaan TIA-epäilyn vuoksi neurologin vastaanotolle. Kattavissa kuvantamis- ja laboratoriotutkimuksissa ei todettu poikkeavaa. Viiden vuoden aikana kohtauksia on esiintynyt noin 20. Todennäköisin selitys on primaarinen verkkokalvon vasospasmi, jossa verkkokalvolle verta tuovat valtimot supistuvat epätarkoituksenmukaisesti.